Abstract
The prevalence of smoking is markedly elevated in schizophrenia. Low smoking cessation rates and reports that some smokers with schizophrenia experience an acute increase in symptoms during attempts to quit smoking, suggest a self-medication model. Alternatively, smoking may modulate medication side effects. The effects of treated and untreated smoking abstinence on psychotic symptoms and medication side effects were examined in this study. Nineteen outpatients with schizophrenia or schizoaffective disorder participated in a randomized, double-blind, balanced crossover study: 1 day of ad libitum smoking followed by 3 days of acute smoking abstinence while wearing 22 mg/day active or placebo transdermal nicotine patches, with a return to 3 days of smoking between patch conditions. Daily symptom and side-effect ratings, nicotine and cotinine blood levels were collected. Twelve subjects completed the study. Neither positive symptoms nor mood symptoms changed. An increase in negative symptoms during the first abstinent day occurred in both placebo and active patch conditions, but was not sustained over subsequent abstinent days. Despite physiological signs of withdrawal, completers did not endorse increased nicotine withdrawal symptoms. Dropouts reported higher withdrawal symptoms, but also had no increase in psychiatric symptoms in either phase of the study. Of note, dyskinesias decreased during abstinence and placebo patch treatment, but increased during abstinence and the active patch conditions. Acute exacerbation of psychiatric symptoms is an unlikely explanation for any difficulty smokers with schizophrenia have in early abstinence.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Addington J, el-Guebaly N, Addington D, Hodgins D . (1997): Readiness to stop smoking in schizophrenia. Can J Psychiat 42: 49–52
Adler LE, Hoffer LD, Wiser A, Freedman R . (1993): Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiat 150: 1856–1861
Andreasen NC . (1982): Negative symptoms in schizophrenia. Arch Gen Psychiat 39: 784–788
Benowitz NL . (1988): Pharmacologic aspects of cigarette smoking and nicotine addiction. NEJM 319: 1318–1330
Covey L, Hughes DC, Glassman AH, Blazer DG, George LK . (1994): Ever-smoking, quitting, and psychiatric disorders: Evidence from the Durham, North Carolina, Epidemiologic Catchment Area. Tobacco Control 3: 222–227
Dalack GW, Meador-Woodruff JH . (1996): Smoking, smoking withdrawal, and schizophrenia: Case reports and a review of the literature. Schizophr Res 22: 133–141
Davis JM . (1976): Comparative doses and costs of antipsychotic medication. Arch Gen Psychiat 33: 858–861
de Leon J, Dadvand M, Canuso C, White AO, Stanilla JK, Simpson GK . (1995): Schizophrenia and smoking: An epidemiological survey in a state hospital. Am J Psychiat 152: 453–455
Decina P, Caracci G, Sandik R, Berman W, Mukherjee S, Scapicchio P . (1990): Cigarette smoking and neuroleptic-induced parkinsonism. Biol Psychiat 28: 502–508
Ereshefsky L, Jann MW, Saklad SR, Davis CM, Richards AL, Burch NR . (1985): Effects of smoking on fluphenazine in psychiatric inpatients. Biol Psychiat 20: 329–332
Freedman R, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A, Polymeropoulos M, Holik J, Hopkins J, Hoff M, Rosenthal J, Waldo MC, Reimherr F, Wender P, Yaw J, Young DA, Breese CR, Adams C, Patterson D, Adler LE, Kruglyak L, Leonard S, Byerley W . (1997): Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci USA 94: 587–592
Glassman AH . (1993): Cigarette smoking: Implications for psychiatric illness. Am J Psychiat 150: 546–553
Goff DC, Henderson DC, Amico E . (1992): Cigarette smoking in schizophrenia: Relationship to psychopathology and medication side effects. Am J Psychiat 149: 1189–1194
Hamilton M . (1960): A rating scale for depression. J Neurol Neurosurg Psychiat 23: 56–62
Hariharan M, VanNoord T, Greden JF . (1988): A high-performance liquid chromatographic method for routine simultaneous determination of nicotine and cotinine in plasma. Clin Chem 34: 724–729
Hatsukami DK, Hughes JR, Pickens RW, Svikis D . (1984): Tobacco withdrawal symptoms: An experimental analysis. Psychopharmacology 84: 231–236
Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom K-O . (1991): The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Brit J Addict 86: 1119–1127
Hedlund JL, Vieweg BW . (1980): The Brief Psychiatric Rating Scale (BPRS): A comprehensive review. J Operational Psychiat 11: 48–64
Hughes JR, Hatsukami D . (1986): Signs and symptoms of tobacco withdrawal. Arch Gen Psychiat 43: 289–294
Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA . (1986): Prevalence of smoking among psychiatric outpatients. Am J Psychiat 413: 993–997
Hughes JR, Higgins ST, Bickel WK . (1994): Common errors in the pharmacologic treatment of drug dependence and withdrawal. Comp Ther 20: 89–94
Jann MW, Saklad SR, Ereshefsky L, Richards AL, Harrington CA, Davis CM . (1986): Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance. Psychopharmacology 90: 468–470
Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB, Charney DS . (1994): Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Arch Gen Psychiat 51: 199–214
McGhee DS, Role LW . (1995): Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Ann Rev Physiol 57: 521–546
Menza MA, Grossman N, Van Horn M, Cody R, Forman N . (1991): Smoking and movement disorders in psychiatric patients. Biol Psychiat 30: 109–115
Munetz MR, Benjamin S . (1988): How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Comm Psychiat 39: 1172–1177
Nilsson A, Waller L, Rosengren A, Adlerberth A, Wilhelmsen L . (1997): Cigarette smoking is associated with abnormal involuntary movements in the general male population—A study of men born in 1933. Biol Psychiat 41: 717–723
Nisell M, Nomikos GG, Hertal P, Panagis G, Svensson TH . (1996): Condition-independent sensitization of locomotor stimulation and mesocortical dopamine release following chronic nicotine treatment in the rat. Synapse 22: 369–381
Nisell M, Nomikos GG, Svensson TH . (1995): Nicotine dependence, midbrain dopamine systems, and psychiatric disorders. Pharmacol & Toxicol 76: 157–162
Overall JE, Gorham DR . (1962): The Brief Psychiatric Rating Scale. Psychol Rep 10: 799–812
Pickworth WB, Bunker EB, Henningfield JE . (1994): Transdermal nicotine: Reduction of smoking with minimal abuse liability. Psychopharmacology 115: 9–14
Psychopharmacology Research Branch, National Institute of Mental Health. (1976): Abnormal Involuntary Movement Scale (AIMS). In Guy W (ed), ECDEU Assessment Manual for Psychopharmacology, revised. Rockville, MD, National Institute of Mental Health, US Dept Health, Education, and Welfare publication (ADM)76-338, pp 534–537
Sanberg PR, Silver AA, Shytle RD, Philipp MK, Cahill DW, Fogelson HM, McConvile BJ . (1997): Nicotine for the treatment of Tourette's syndrome. Pharmacol & Therapeu 74: 21–25
Sandyk R, Kay SR . (1991): Tobacco addiction as a marker of age at onset of schizophrenia. Intern Neurosci 57: 259–262
Simpson GM, Angus JWS . (1970): A rating scale for extrapyramidal side effects. Acta Psychiat Scand 212: 11–19
Spitzer RL, Williams JBW, Gibbon M, First MB . (1989): Structured Clinical Interview for DSM-III-R- Patient Version (SCID-P, 9/1/89 Version). New York, NY: Biometrics Research Department, New York State Psychiatric Institute
Wirshing WC, Engle J, Levin E, et al (1989): The acute effects of smoking on tardive dyskinesia. In 1989, New Research Program and Abstracts. San Francisco, CA: American Psychiatric Association
Yassa R, Lal S, Korpassy A, Ally J . (1987): Nicotine exposure and tardive dyskinesia. Biol Psychiat 22: 67–72
Ziedonis DM, George TP . (1997): Schizophrenia and nicotine use: Report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr Bull 23: 247–254
Acknowledgements
This work was supported by a Research Advisory Group (RAG) Grant from the Department of Veterans Affairs to GWD and by GCRC Grant MO1-RR00042. Versions of this work were presented at the 150th annual meeting of the American Psychiatric Association, San Diego, California, May 1997, and the 3rd annual scientific conference of the Society for Research on Nicotine and Tobacco, Nashville, Tennessee, June, 1997. The authors acknowledge the assistance of Gina Baslock and Dr. Victoria Florante.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dalack, G., Becks, L., Hill, E. et al. Nicotine Withdrawal and Psychiatric Symptoms in Cigarette Smokers with Schizophrenia. Neuropsychopharmacol 21, 195–202 (1999). https://doi.org/10.1016/S0893-133X(98)00121-3
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1016/S0893-133X(98)00121-3
Keywords
This article is cited by
-
Achieving Smoking Cessation in Individuals with Schizophrenia: Special Considerations
CNS Drugs (2017)
-
Dyskinesia in an unmedicated adolescent with a 5-year history of tobacco use: a case report
Journal of Medical Case Reports (2016)
-
The separate and combined effects of monoamine oxidase inhibition and nicotine on P50 sensory gating
Psychopharmacology (2015)
-
Movement disorders: Neurodevelopment and neurobehavioural expression
Journal of Neural Transmission (2007)
-
Treatment consideration and manifest complexity in comorbid neuropsychiatric disorders
Neurotoxicity Research (2007)
